Methods of treating myopathies with anti-pro/latent myostatin antibodies
AssigneeScholar Rock, Inc.
InventorsMichelle Straub, Dong Yun Lee, William K. McConaughy, Katherine Jane Turner, Nagesh K. Mahanthappa, Justin W. Jackson
Life of this patent
Estimating the term…
Abstract
Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
Claims19
A method of treating a subject having, or at risk of developing, Duchenne's muscular dystrophy, facioscapulohumeral muscular dystrophy, or Becker's muscular dystrophy, the method comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to pro/latent myostatin, and wherein the antibody or antigen-binding fragment thereof comprises six complementarity determining regions (CDRs):
- CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, wherein:
- a) CDRH1 comprises the amino acid sequence of SEQ ID NO:
- 1,
- CDRH2 comprises the amino acid sequence of SEQ ID NO:
- 4,
- CDRH3 comprises the amino acid sequence of SEQ ID NO:
- 10,
- CDRL1 comprises the amino acid sequence of SEQ ID NO:
- 12,
- CDRL2 comprises the amino acid sequence of SEQ ID NO:
- 18, and
- CDRL3 comprises the amino acid sequence of SEQ ID NO:
- 22, wherein the CDR sequences are numbered according to Kabat numbering system;
- or
- b) CDRH1 comprises the amino acid sequence of SEQ ID NO:
- 2,
- CDRH2 comprises the amino acid sequence of SEQ ID NO:
- 5,
- CDRH3 comprises the amino acid sequence of SEQ ID NO:
- 10,
- CDRL1 comprises the amino acid sequence of SEQ ID NO:
- 13,
- CDRL2 comprises the amino acid sequence of SEQ ID NO:
- 19, and
- CDRL3 consists of the amino acid sequence of SEQ ID NO:
- 22, wherein the CDR sequences are numbered according to IMGT numbering system.
A method of treating a subject having, or at risk of developing, amyotrophic lateral sclerosis (ALS), the method comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to pro/latent myostatin, and wherein the antibody or antigen-binding fragment thereof comprises six complementarity determining regions (CDRs):
- CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, wherein:
- a) CDRH1 comprises the amino acid sequence of SEQ ID NO:
- 1,
- CDRH2 comprises the amino acid sequence of SEQ ID NO:
- 4,
- CDRH3 comprises the amino acid sequence of SEQ ID NO:
- 10,
- CDRL1 comprises the amino acid sequence of SEQ ID NO:
- 12,
- CDRL2 comprises the amino acid sequence of SEQ ID NO:
- 18, and
- CDRL3 comprises the amino acid sequence of SEQ ID NO:
- 22, wherein the CDR sequences are numbered according to Kabat numbering system;
- or
- b) CDRH1 comprises the amino acid sequence of SEQ ID NO:
- 2,
- CDRH2 comprises the amino acid sequence of SEQ ID NO:
- 5,
- CDRH3 comprises the amino acid sequence of SEQ ID NO:
- 10,
- CDRL1 comprises the amino acid sequence of SEQ ID NO:
- 13,
- CDRL2 comprises the amino acid sequence of SEQ ID NO:
- 19, and
- CDRL3 consists of the amino acid sequence of SEQ ID NO:
- 22, wherein the CDR sequences are numbered according to IMGT numbering system.
A method of treating a subject having osteogenesis imperfecta, the method comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to pro/latent myostatin, and wherein the antibody or antigen-binding fragment thereof comprises six complementarity determining regions (CDRs):
- CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, wherein:
- a) CDRH1 comprises the amino acid sequence of SEQ ID NO:
- 1,
- CDRH2 comprises the amino acid sequence of SEQ ID NO:
- 4,
- CDRH3 comprises the amino acid sequence of SEQ ID NO:
- 10,
- CDRL1 comprises the amino acid sequence of SEQ ID NO:
- 12,
- CDRL2 comprises the amino acid sequence of SEQ ID NO:
- 18, and
- CDRL3 comprises the amino acid sequence of SEQ ID NO:
- 22, wherein the CDR sequences are numbered according to Kabat numbering system;
- or
- b) CDRH1 comprises the amino acid sequence of SEQ ID NO:
- 2,
- CDRH2 comprises the amino acid sequence of SEQ ID NO:
- 5,
- CDRH3 comprises the amino acid sequence of SEQ ID NO:
- 10,
- CDRL1 comprises the amino acid sequence of SEQ ID NO:
- 13,
- CDRL2 comprises the amino acid sequence of SEQ ID NO:
- 19, and
- CDRL3 consists of the amino acid sequence of SEQ ID NO:
- 22, wherein the CDR sequences are numbered according to IMGT numbering system.
Dependencies are inferred from the claim text.